48
Participants
Start Date
November 21, 2024
Primary Completion Date
October 31, 2029
Study Completion Date
October 31, 2029
Vimseltinib
Administered orally
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
Duke University Hospital, Durham
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Emory University Winship Cancer Institute, Atlanta
RECRUITING
AdventHealth Orlando, Orlando
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Tristar Bone Marrow Transplant, Nashville
RECRUITING
University of Kentucky Markey Cancer Center, Lexington
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Oncology Hematology Care Clinical Trials, LLC, Cincinnati
RECRUITING
Henry Ford Cancer Institute, Detroit
RECRUITING
Avera Cancer Institute, Sioux Falls
RECRUITING
University of Illinois Medical Center - Hematology & Oncology, Chicago
RECRUITING
Washington University School of Medicine - Siteman Cancer Center, St Louis
RECRUITING
University of Kansas Cancer Center-Westwood, Westwood
RECRUITING
St. David's South Austin Medical Center, Austin
RECRUITING
Intermountain Health, Salt Lake City
RECRUITING
Ronald Regan UCLA Medical Center, Los Angeles
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
University of California Irvine Health, Orange
RECRUITING
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Deciphera Pharmaceuticals, LLC
INDUSTRY